Peroxisome proliferator-activated receptor γ and atherosclerosis

被引:0
|
作者
Nikolaus Marx
机构
[1] University of Ulm,Department of Internal Medicine II
来源
Current Hypertension Reports | 2002年 / 4卷
关键词
Rosiglitazone; Troglitazone; Arterioscler Thromb Vasc Biol; Foam Cell Formation; Human Atherosclerotic Plaque;
D O I
暂无
中图分类号
学科分类号
摘要
Within the past couple of years, peroxisome proliferator-activated receptor γ (PPARγ), a nuclear transcription factor expressed in vascular cells, has received growing interest in vascular biology and atherosclerosis research. Initially, PPARγ was identified as a regulator of gene expression in lipid metabolism and adipogenesis, but recent data in monocyte/macrophages, endothelial cells, and vascular smooth muscle cells suggest that PPARγ might have anti-inflammatory effects in atherogenesis. However, with growing insight, there is much controversy about potential anti- or proatherosclerotic effects. This review will focus on these aspects and discuss what PPARγ activation in vascular cells could mean for atherogenesis and the development of atherosclerosis.
引用
收藏
页码:71 / 77
页数:6
相关论文
共 50 条
  • [1] Peroxisome proliferator-activated receptor-γ agonists in atherosclerosis:: current evidence and future directions
    Roberts, AW
    Thomas, A
    Rees, A
    Evans, M
    CURRENT OPINION IN LIPIDOLOGY, 2003, 14 (06) : 567 - 573
  • [2] Peroxisome proliferator-activated receptor-γ and its agonists in hypertension and atherosclerosis: Mechanisms and clinical implications
    Halabi C.M.
    Sigmund C.D.
    American Journal of Cardiovascular Drugs, 2005, 5 (6) : 389 - 398
  • [3] Peroxisome proliferator-activated receptor-γ and lipodystrophy
    Tantsma, Jouke T.
    Rabelink, Ton J.
    FUTURE LIPIDOLOGY, 2006, 1 (04): : 455 - 462
  • [4] The role of peroxisome proliferator-activated receptor γ in blood pressure regulation
    Milton Hamblin
    Lin Chang
    Jifeng Zhang
    Y. Eugene Chen
    Current Hypertension Reports, 2009, 11 : 239 - 245
  • [5] Peroxisome proliferator-activated receptors.
    Ziouzenkova O.
    Perrey S.
    Marx N.
    Bacqueville D.
    Plutzky J.
    Current Atherosclerosis Reports, 2002, 4 (1) : 59 - 64
  • [6] Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms.
    Plutzky J.
    Current Atherosclerosis Reports, 2000, 2 (4) : 327 - 335
  • [7] Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma
    Sauer, Sascha
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2015, 36 (10) : 688 - 704
  • [8] Mode of Peroxisome Proliferator-Activated Receptor γ Activation by Luteolin
    Puhl, Ana C.
    Bernardes, Amanda
    Silveira, Rodrigo L.
    Yuan, Jing
    Campos, Jessica L. O.
    Saidemberg, Daniel M.
    Palma, Mario S.
    Cvoro, Aleksandra
    Ayers, Stephen D.
    Webb, Paul
    Reinach, Peter S.
    Skaf, Munir S.
    Polikarpov, Igor
    MOLECULAR PHARMACOLOGY, 2012, 81 (06) : 788 - 799
  • [9] Curcumin is not a ligand for peroxisome proliferator-activated receptor-γ
    Narala, Venkata R.
    Smith, Monica R.
    Adapala, Ravi K.
    Ranga, Rajesh
    Panati, Kalpana
    Moore, Bethany B.
    Leff, Todd
    Reddy, Vudem D.
    Kondapi, Anand K.
    Reddy, Raju C.
    GENE THERAPY AND MOLECULAR BIOLOGY, 2009, 13 (01) : 20 - 25
  • [10] The Cardiovascular Effects of Peroxisome Proliferator-activated Receptor Agonists
    Friedland, Sayuri N.
    Leong, Aaron
    Filion, Kristian B.
    Genest, Jacques
    Lega, Iliana C.
    Mottillo, Salvatore
    Poirier, Paul
    Reoch, Jennifer
    Eisenberg, Mark J.
    AMERICAN JOURNAL OF MEDICINE, 2012, 125 (02) : 126 - 133